
Monday, June 09, 2025 4:57:00 PM
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 6, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2025. Of the 11,314,835 shares outstanding as of the record date, 7,629,048 shares, or 67.43%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
https://www.sec.gov/Archives/edgar/data/1094038/000110465925057836/tm2517533d1_8k.htm
PROTECT YOUR ASS-ets!!
Recent MRKR News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2025 12:00:41 PM
- Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma • GlobeNewswire Inc. • 06/17/2025 12:00:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/09/2025 08:13:33 PM
- Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma • GlobeNewswire Inc. • 05/20/2025 12:00:09 PM
- Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies • GlobeNewswire Inc. • 05/19/2025 12:00:12 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2025 08:45:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2025 08:43:44 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2025 08:42:07 PM
- Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference • GlobeNewswire Inc. • 04/01/2025 12:00:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2025 12:48:09 PM
- Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results • GlobeNewswire Inc. • 03/31/2025 12:45:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 12:18:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2025 09:00:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/04/2025 10:08:04 PM
- Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 02/25/2025 12:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2025 10:02:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 10:20:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 10:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2025 10:17:32 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/04/2025 09:05:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/04/2025 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2025 09:05:26 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM